This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
by Zacks Equity Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
by Zacks Equity Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
by Zacks Equity Research
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
Why Amarin (AMRN) Stock Might be a Great Pick
by Zacks Equity Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
by Zacks Equity Research
The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
by Zacks Equity Research
Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.
Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
New Strong Sell Stocks for May 13th
by Zacks Equity Research
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.
Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.
Amarin (AMRN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Amarin (AMRN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Amarin (AMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.